What You Should Know:
- Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early identification of patients who may be at risk of cardiac amyloidosis.
- Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a
Read More
hyperkalemia
AliveCor Receives “Breakthrough Device” Designation from FDA for Bloodless Hyperkalemia Test
AliveCor, a Mountain View, CA-based digital health startup developing solutions to transform cardiac care, announced on Monday received “breakthrough device” designation from the U.S. Food and Drug Administration for their bloodless hyperkalemia test. Developed with Mayo Clinic, AliveCor’s KardiaK Platform screens for elevated levels of blood potassium – hyperkalemia, without requiring any blood from the patient.This designation signals that the FDA will consider the technology on an
Read More
